Takuma Goto

Dr. Takuma Goto

medicine, Asahikawa Medical University, Asahikawa, Hokkaidō, Japan
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2018 in BMC Cancer
Verified
Journal Article
Open access
PDF file
TGTakuma Goto
Takuma Goto
MFMikihiro Fujiya
Mikihiro Fujiya
HKHiroaki Konishi
Hiroaki Konishi
JSJunpei Sasajima
Junpei Sasajima
SFShugo Fujibayashi
Shugo Fujibayashi
TOToshikatsu Okumura
Toshikatsu Okumura
Pancreatic cancer is associated with an extremely poor prognosis, so new biomarkers that can detect the initial stages are urgently needed. The significance of serum microRNA (miR) levels in pancreatic neoplasm such as pancreatic cancer and intraductal papillary mucinous neoplasm (IPMN) diagnosis remains unclear. We herein evaluated the usefulness of miRs enclosed in serum exosomes (ExmiRs) as diagnostic markers. The ExmiRs from patients with pancreatic cancer (n = 32) or IPMN (n = 29), and patients without neoplasms (controls; n = 22) were enriched using ExoQuick-TC™. The expression of ExmiRs was evaluated using a next-generation sequencing analysis, and the selected three miRs through this analysis were confirmed by a quantitative real-time polymerase chain reaction. The expression of ExmiR-191, ExmiR-21 and ExmiR-451a was significantly up-regulated in patients with pancreatic cancer and IPMN compared to the controls (p < 0.05). A receiver operating characteristic curve analysis showed that the area under the curve and the diagnostic accuracy of ExmiRs were 5–20% superior to those of three serum bulky circulating miRs (e.g.; ExmiR-21: AUC 0.826, accuracy 80.8%. Circulating miR-21: AUC 0.653, accuracy 62.3%). In addition, high ExmiR-451a was associated with mural nodules in IPMN (p = 0.010), and high ExmiR-21 was identified as a candidate prognostic factor for the overall survival (p = 0.011, HR 4.071, median OS of high-ExmiR-21: 344 days, median OS of low-ExmiR-21: 846 days) and chemo-resistant markers (p = 0.022). The level of three ExmiRs can thus serve as early diagnostic and progression markers of pancreatic cancer and IPMN, and considered more useful markers than the circulating miRs (limited to these three miRs).

29 June 2022 in Digestive Endoscopy
Verified
Journal Article
Closed access
MKMasayuki Kitano
Masayuki Kitano
MYMakoto Yoshida
Makoto Yoshida
RAREIKO ASHIDA
REIKO ASHIDA
EKEmiri Kita
Emiri Kita
AKAkio Katanuma
Akio Katanuma
HYHiroki Yamaue
Hiroki Yamaue

15 March 2020 in Gut and Liver
Verified
Journal Article
Open access
PDF file
Masaki KuwataniMasaki Kuwatani
Masaki Kuwatani
TNToru Nakamura
Toru Nakamura
THTsuyoshi Hayashi
Tsuyoshi Hayashi
YKYasutoshi Kimura
Yasutoshi Kimura
MOMichihiro Ono
Michihiro Ono
H(Hokkaido Pancreatic Cancer Study Group (HOPS)
Hokkaido Pancreatic Cancer Study Group (HOPS)
Masaki Kuwatani, Toru Nakamura, Tsuyoshi Hayashi, Yasutoshi Kimura, Michihiro Ono, Masayo Motoya, Koji Imai, Keisuke Yamakita, Takuma Goto, Kuniyuki Takahashi, Hiroyuki Maguchi, Satoshi Hirano, and Hokkaido Pancreatic Cancer Study Group (HOPS). Gut and Liver 2020;14:269-73. https://doi.org/10.5009/gnl18573

24 June 2021 in Cancers
Verified
Journal Article
Open access
PDF file
HKHiroaki Konishi
Hiroaki Konishi
SKShin Kashima
Shin Kashima
TGTakuma Goto
Takuma Goto
KAKatsuyoshi Ando
Katsuyoshi Ando
ASAki Sakatani
Aki Sakatani
MFMikihiro Fujiya
Mikihiro Fujiya
Previous investigations have indicated that RNA-binding proteins (RBPs) are key molecules for the development of organs, differentiation, cell growth and apoptosis in cancer cells as well as normal cells. A bioinformatics analysis based on the mRNA expression and a somatic mutational database revealed the association between aberrant expression/mutations of RBPs and cancer progression. However, this method failed to detect functional alterations in RBPs without changes in the expression, thus leading to false negatives. To identify major tumor-associated RBPs, we constructed an siRNA library based on the database of RBPs and assessed the influence on the growth of colorectal, pancreatic and esophageal cancer cells. A comprehensive analysis of siRNA functional screening findings using 1198 siRNAs targeting 416 RBPs identified 41 RBPs in which 50% inhibition of cell growth was observed in cancer cells. Among these RBPs, 12 showed no change in the mRNA expression and no growth suppression in non-cancerous cells when downregulated by specific siRNAs. We herein report for the first time cancer-promotive RBPs identified by a novel functional assessment using an siRNA library of RBPs combined with expressional and mutational analyses.

14 August 2017 in Annals of Clinical Microbiology and Antimicrobials
Verified
Journal Article
Open access
PDF file
KTKazuyuki Tanaka
Kazuyuki Tanaka
MFMikihiro Fujiya
Mikihiro Fujiya
ASAki Sakatani
Aki Sakatani
SFShugo Fujibayashi
Shugo Fujibayashi
YNYoshiki Nomura
Yoshiki Nomura
TOToshikatsu Okumura
Toshikatsu Okumura
Helicobacter pylori (H. pylori) eradication rarely develops into antibiotic-associated hemorrhagic colitis (AAHC), in which the etiology of colitis remains unclear. We herein report a rare case of AAHC caused by second-line therapy for H. pylori eradication. A 65-year-old female was administered second-line therapy for H. pylori composed of 1500 mg of amoxicillin, 500 mg of metronidazole and 40 mg of vonoprazan for 7 days because of first-line therapy failure. A day after completing second-line therapy, she complained of abdominal pain and hematochezia. Colonoscopy revealed a hemorrhage and edematous mucosa with no transparent vascular pattern in the transverse colon. A bacterial culture detected Klebsiella oxytoca (K. oxytoca), but no other pathogenic bacteria. A drug-induced lymphocyte stimulation test (DLST) showed positive reactions for both amoxicillin and metronidazole. According to these findings, the patient was diagnosed with AAHC. Bowel rest for 6 days relieved her abdominal pain and hematochezia. The present case developed AAHC caused by second-line therapy for H. pylori eradication. The pathogenesis is considered to be associated with microbial substitution as well as a delayed-type allergy to antibiotics, suggesting that AAHC is a potential adverse event of second-line therapy for H. pylori eradication.

17 November 2020 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
TGTakuma Goto
Takuma Goto
HSHiroya Saito
Hiroya Saito
JSJunpei Sasajima
Junpei Sasajima
TKToru Kawamoto
Toru Kawamoto
AFAkihiro Fujinaga
Akihiro Fujinaga
MFMikihiro Fujiya
Mikihiro Fujiya
Synopsis: A new combination therapy consisting of intraarterial chemotherapy plus radiotherapy was demonstrated to have the potential to improve the response rate and survival time in patients with unresectable biliary tract cancer. Purpose: We retrospectively investigated the effectiveness and safety of a new combination therapy consisting of intraarterial chemotherapy plus radiation therapy (AI+RT), which may have the potential to improve unresectable biliary tract cancer (BTC). Methods: We retrospectively reviewed 52 BTC cases treated with AI+RT and analyzed the anti-tumor effect, survival time and adverse events. The AI+RT regimen consisted of one-shot intraarterial chemotherapy (AI) at the first angiography session, almost 6 months of reservoir AI (5-FU and cisplatin, q/week) and external radiation with a maximum dose of 50.6 Gy. Results: The response rate and disease control rate were high, at 40.4% and 96.2%, respectively, and the median overall and progression-free survival time were 463 and 431 days; thus, long-term survival was achieved. A univariate analysis identified 12 prognostic factors, and a performance status of 2 (hazard ratio [HR]: 4.82, p=0.02), jaundice (HR: 3.22, p<0.01), peritoneal dissemination (HR: 22.5, p<0.01), number of AI (HR: 0.35, p=0.01) and response to AI+RT (HR: 0.23, p<0.01) were extracted as significant prognostic factors in a multivariate analysis. The following: grade ≥3 adverse events occurred: leucopenia (11.5%), neutropenia (1.9%), anemia (15.4%), thrombocytopenia (11.5%), anorexia (3.8%), gastroduodenal ulcer (25.0%), and cholangitis (23.1%). There were no cases of treatment-related death. Conclusions: AI+RT was shown to contribute to a high response rate and prolonged survival in patients with unresectable BTC. A sufficient number of AI and the response to this therapy were thought to be significant prognostic factors in patients receiving AI+RT. Advances in multidisciplinary therapies, such as AI+RT, which was described in the present study, are also considered to be important for the future.